|
Canada-0-FERTILIZER कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- AMGEN | Tarlatamab Clinical Trials
DeLLphi Clinical Trials are available to patients with Small-Cell Lung Cancer (SCLC) Amgen Oncology is testing the investigational drug tarlatamab to see how safe and effective it is at treating patients who have small-cell lung cancer (SCLC) DeLLphi-305 (Extensive-Stage SCLC)
- ASCO 2024 Prostate Cancer - UroToday
ASCO 2024: DeLLpro-300: Phase 1b Study of Tarlatamab in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer ASCO 2024: Nivolumab and Ipilimumab for Metastatic Prostate Cancer with an Immunogenic Signature: The NEPTUNES Multi-Centre Two-Cohort, Biomarker-Selected Phase 2 Trial
- AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
Tarlatamab is being investigated in multiple studies, including DeLLphi-301, a potentially registrational Phase 2 study in third line or later relapsed refractory SCLC; DeLLphi-303, a Phase 1b study testing tarlatamab in combination with standard of care therapies in first-line SCLC; DeLLphi-302, a Phase 1b combination study with AMG 404 in
- AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE . . .
In the Phase 1 DeLLphi-300 study, IMDELLTRA showed responses in 23 4% of patients with encouraging durability in heavily pre-treated patients with SCLC 17 In the Phase 2 DeLLphi-301 study, and DeLLpro-300, a Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer 18
- Tarlatamab Shows Encouraging Activity in Phase 1 Trial in . . . - UroToday
ASCO 2024: DeLLpro-300: Phase 1b Study of Tarlatamab in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer DLL3 as a Neuroendocrine Carcinoma Target DLL3 Targeting Bispecifics: A New Hope for Tough-to-Treat Prostate Cancer Patients - Rahul Aggarwal
- Home - ClinicalTrials. gov
We would like to show you a description here but the site won’t allow us
- タルラタマブ で 神経内分泌前立腺がん-臨床試験登録-ICH GCP
神経内分泌前立腺癌の参加者におけるタルラタマブ(AMG 757)の研究 (DeLLpro-300) 2024年10月22日 更新者: Amgen De Novoまたは治療緊急神経内分泌前立腺癌の被験者におけるデルタ様タンパク質3半減期延長二重特異性T細胞エンゲージャーAMG 757の安全性、忍容性
- Tarlatamabs approval in Europe: When is it coming (and how not to wait . . .
The results from the Phase 1 DeLLpro-300 trial focusing on neuroendocrine prostate cancer are expected after August 2025 Is tarlatamab FDA approved? Yes, Imdelltra (tarlatamab) received an accelerated approval by the FDA in May 2024 In order to maintain its approved status, tarlatamab will need to confirm its clinical benefits in additional
- FDA Grants Priority Review to Tarlatamab in Advanced SCLC
The FDA has granted priority review approval for the biologics license application (BLA) for tarlatamab for patients with advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy 1 The basis of this BLA comes from results from the phase 2 DeLLphi-301 trial which showed among patients with previously treated SCLC given tarlatamab, antitumor activity was
- 潜力巨大!双抗“新星”药物Tarlatamab治疗小细胞肺癌效果积极
DeLLpro-300试验,主要评估Tarlatama在神经内分泌前列腺癌患者中的疗效,目前已完成患者招募。 Amgen公司还计划开展另外两项关于Tarlatamab的3期临床试验,主要评估Tarlatamab在小细胞肺癌早期治疗阶段的疗效。
|
|